In late Oct., Jiangsu Sword Agrochemicals Co., Ltd. (Jiangsu Sword) revealed that its wholly-owned subsidiary Ningxia Surongda Chemical Co., Ltd. (Ningxia Surongda) had brought the lines for 76,000 t/a pesticide intermediates in the Ningxia production base into trial run since 30 Sept., 2022. According to its plan, the trial production will last until 29 March, 2023. Intermediate products and their designed capacity planned in this large-scale project are: 20,000 t/a hydrazine hydrate, 10,000 t/a 1,2,4-triazole, 6,000 t/a thiocarbohydrazide, 10,000 t/a epoxide, 10,000 t/a pinacolone, 8,000 t/a p-chlorobenzaldehyde, 6,000 t/a triazinone and 6,000 t/a 1,1-dichloropinacolin.
Jiangsu Sword is a backbone pesticide manufacturer in China, engaged in R&D, production and sale of pesticides. It established Ningxia Surongda in Feb. 2018 in the New Material Park of Ningdong Energy Chemical Industry Base, Yinchuan City, Ningxia Hui Autonomous Region. It plans to build the new subsidiary into its Ningxia production base.
Before setting up the Ningxia production base, Jiangsu Sword already had two bases in Yancheng City of Jiangsu Province, one in Jianhu County Economic Development Zone and the other in the Yanhai Chemical Industrial Park of Binhai County. The former, Jianhu base, focuses on pesticide formulation production, and the latter, Binhai base, mainly produces pesticide intermediates and pesticide technical products. However, operation in the two bases in Jiangsu has been challenged by workplace safety inspections and environmental protection inspections in recent years. Especially after the severe explosion in Xiangshui County on 21 March, 2019, the Binhai base was then ordered to suspend for rectification by local government.
The Binhai base once had, before the suspension, active production capacity of 1,000 t/a triadimefon TC, 400 t/a triadimenol TC, 2,000 t/a tebuconazole TC, 1,000 t/a propineb TC, 1,000 t/a flutriafol TC, 200 t/a hexaconazole TC, 50 t/a bitertanol TC, 200 t/a diniconazole TC, 500 t/a cyproconazole TC, 200 t/a azoxystrobin TC, 1,000 t/a bentazone TC, 1,800 t/a metribuzin TC, 1,000 t/a nitenpyram TC, 1,000 t/a acetamiprid TC, 500 t/a paclobutrazol TC, 50 t/a uniconazole TC, 2,600 t/a pinacolone, 1,300 t/a 1-chloropinacolone, 2,500 t/a 1,1-dichloropinacolin and 3,000 t/a triazinone. After several rounds of rectification, some production lines have resumed production—as of 17 Oct., 2022, the lines for the four intermediates and cyproconazole TC, tebuconazole TC, metribuzin TC, triadimefon TC and triadimenol TC had been approved of resumption. On its way to restart production, the Binhai base also took the opportunity to shed the lines for nitenpyram TC, acetamiprid TC, flutriafol TC and hexaconazole TC. And currently, there is no update on the progress of resumption of the production capacity for the rest products in the Binhai base.